Lantus in South Korea: prescription, pharmacy and pricing
Lantus (Insulin Glargine) is available in South Korea under the regulatory framework of MFDS (Ministry of Food and Drug Safety). This page summarises how the medication is prescribed and dispensed locally, what insurance or the public system cover, and which options exist for legally and safely accessing Lantus 100 IU/mL.
- Regulator
- MFDS (Ministry of Food and Drug Safety)
- Currency
- KRW
- Active ingredients
- Insulin Glargine
- Available dosages
- 100 IU/mL
Prescription status in South Korea
In South Korea, prescription medicines (전문의약품) are dispensed only against a doctor's prescription, while general medicines (일반의약품) are sold OTC at pharmacies. The 2000 medical reform separated dispensing from prescribing — doctors prescribe, pharmacists dispense. Lantus contains the active ingredient Insulin Glargine, in the Diabetes Treatment class, and its classification in South Korea follows the standard rules of MFDS (Ministry of Food and Drug Safety).
Pharmacy dispensing
Korean pharmacies (약국) are licensed by the MFDS and present in every neighbourhood, often clustered near clinics. Pharmacists verify each prescription and provide medication counselling at dispensing, with the National Health Insurance Service covering most prescription costs. The pharmacist is the most reliable local source of information on stock, authorised substitutions (generic vs brand) and specific precautions for Lantus at the available strengths (100 IU/mL).
Online and tele-prescribing access
Online prescription dispensing is heavily restricted in South Korea — telemedicine and remote prescribing were expanded only temporarily during COVID-19 and remain limited. Direct online sale of prescription medication is not permitted; consumers can browse OTC products on chain-pharmacy websites. Buying Lantus from unauthorised sellers or without local verification exposes the user to counterfeit medication and unmonitored use of Insulin Glargine.
When Lantus is prescribed
The medication is indicated in adults and paediatric patients with type 1 diabetes mellitus, and in adults with type 2 diabetes mellitus when basal insulin is required.
Pricing and availability in KRW
Retail pricing in South Korea depends on the strength (100 IU/mL), whether the original brand or an authorised generic is dispensed, and insurance or public-system coverage. The difference between brand and generic is usually the most meaningful economic lever for ongoing use. Comparing prices at two or more locally authorised pharmacies before first refill is recommended.
Frequently asked questions
Do I need a prescription for Lantus in South Korea? ▾
In South Korea, prescription medicines (전문의약품) are dispensed only against a doctor's prescription, while general medicines (일반의약품) are sold OTC at pharmacies. The 2000 medical reform separated dispensing from prescribing — doctors prescribe, pharmacists dispense. In practice, Lantus follows the status of its active ingredient Insulin Glargine in the regulatory system of MFDS (Ministry of Food and Drug Safety).
Is generic Lantus available in South Korea? ▾
Authorised generics of Insulin Glargine are typically available in South Korea at a lower cost than branded Lantus, with bioequivalence required by MFDS (Ministry of Food and Drug Safety). Substitution is handled by the pharmacist under local equivalence rules.
How much does Lantus cost in KRW? ▾
Prices in KRW vary by pharmacy and by strength (100 IU/mL). Authorised generics of Insulin Glargine are usually substantially cheaper than the brand and are the typical economic reference point for ongoing use in South Korea.
Lantus in other countries
- the United StatesFDA (Food and Drug Administration)
- the United KingdomMHRA (Medicines and Healthcare products Regulatory Agency)
- SpainAEMPS (Agencia Española de Medicamentos y Productos Sanitarios)
- MexicoCOFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios)
- ArgentinaANMAT (Administración Nacional de Medicamentos, Alimentos y Tecnología Médica)
- GermanyBfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)
- FranceANSM (Agence nationale de sécurité du médicament et des produits de santé)
- ItalyAIFA (Agenzia Italiana del Farmaco)
- BrazilANVISA (Agência Nacional de Vigilância Sanitária)
- CanadaHealth Canada
- JapanPMDA (Pharmaceuticals and Medical Devices Agency)
- AustriaBASG (Federal Office for Safety in Health Care)
- SwitzerlandSwissmedic (Swiss Agency for Therapeutic Products)
- AustraliaTGA (Therapeutic Goods Administration)
- ColombiaInvima (National Food and Drug Surveillance Institute)
- ChileISP (Instituto de Salud Pública de Chile, Public Health Institute)
The information on this website is provided for reference and educational purposes only. It does not replace consultation with a qualified healthcare professional.